Penetration of linezolid and tedizolid in cerebrospinal fluid of mouse and impact of blood–brain barrier disruption
Clinical and Translational Science · 2025-01 · 18 (1)
DOI: 10.1111/cts.70100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 20.01.2025. Verfasst von Marin Lahouati und 5 weiteren Autor:innen. Beteiligte Einrichtung: Service de Pharmacie Clinique, CHU de Bordeaux, Hôpital Pellegrin, Bordeaux, France. Hauptthemen laut MEDLINE: Linezolid, Blood-Brain Barrier, Anti-Bacterial Agents, Organophosphates. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Penetration of antimicrobial treatments into the cerebrospinal fluid is essential to successfully treat infections of the central nervous system. This penetration is hindered by different barriers, including the blood–brain barrier, which is the most impermeable. However, inflammation may lead to structural alterations of these barriers, modifying their permeability. The impact of blood–brain barrier disruption on linezolid and tedizolid (antibiotics that may be alternatives to treat nosocomial meningitis) penetration in cerebrospinal fluid (CSF) remains unknown. The aim of this study is to evaluate the impact of blood brain barrier disruption on CSF penetration of linezolid and tedizolid. Female C57BI/6 J mice were used. Blood–brain barrier disruption was induced by an intraperitoneal administration of lipopolysaccharide. Linezolid (40 mg/kg) or tedizolid‐phosphate (20 mg/kg) were injected intraperitoneally. All the plasma and CSF samples were analyzed with a validated UPLC‐MS/MS method. Pharmacokinetic parameters were calculated using a non‐compartmental approach based on the free drug concentration. The penetration ratio from the plasma into the CSF was calculated by the AUC 0‐8h (Area Under Curve) ratio (AUC 0‐8hCSF /AUC 0‐8hplasma ). Linezolid penetration ratio was 46.5% in control group and 46.1% in lipopolysaccharide group. Concerning tedizolid, penetration ratio was 5.5% in control group and 15.5% in lipopolysaccharide group. In conclusion, CSF penetration of linezolid is not impacted by blood–brain barrier disruption, unlike tedizolid, whose penetration ratio increased.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Service de Pharmacie Clinique, CHU de Bordeaux, Hôpital Pellegrin, Bordeaux, France.
- INSERM U1034, Biologie des Maladies Cardiovasculaires, Université de Bordeaux, Pessac, France.
- Laboratoire de Pharmaco-Toxicologie Biologique et Médico-Légale, CH Tarbes-Lourdes, Tarbes, France.
ORCID-Profile: Fabien Xuereb
Zitieren
APA
Lahouati, M., Oudart, M., Alzieu, P., Chapouly, C., Petitcollin, A., & Xuereb, F. (2025). Penetration of linezolid and tedizolid in cerebrospinal fluid of mouse and impact of blood–brain barrier disruption. Clinical and Translational Science, 18(1). https://doi.org/10.1111/cts.70100
Vancouver
Lahouati M, Oudart M, Alzieu P, Chapouly C, Petitcollin A, Xuereb F. Penetration of linezolid and tedizolid in cerebrospinal fluid of mouse and impact of blood–brain barrier disruption. Clinical and Translational Science. 2025;18(1). doi:10.1111/cts.70100
BibTeX
@article{Lahouati2025,
author = {Lahouati, Marin and Oudart, Mélanie and Alzieu, Philippe and Chapouly, Candice and Petitcollin, Antoine and Xuereb, Fabien},
title = {Penetration of linezolid and tedizolid in cerebrospinal fluid of mouse and impact of blood–brain barrier disruption},
journal = {Clinical and Translational Science},
year = {2025},
volume = {18},
number = {1},
doi = {10.1111/cts.70100}
}
EUVIMED